Drug Trial Radar · NCT07812597
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Oct 12, 2026
Primary completion
Jan 13, 2028
Study completion Mar 24, 2028
Sponsor
- Lead sponsor
- Beijing QL Biopharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.
Conditions
- Obesity
Interventions
zovaglutide Arm 1Drug
Zovaglutide will be administered via subcutaneous (SC) injection.
zovaglutide Arm 2Drug
Zovaglutide will be administered via subcutaneous (SC) injection.
semaglutideDrug
Semaglutide will be administered via subcutaneous (SC) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomizationTime frame: from week 20 (randomization) to week 36
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Huizhou Central People's Hospital
Huizhou, Guangdong, China
Handan First Hospital
Handan, Hebei, China
Hebei Petro China Cental Hospital
Langfang, Hebei, China
Harbin Medical University Affiliated Fourth Hospital
Harbin, Heilongjiang, China
The First Affiliated of Nanyang Medical College
Nanyang, Henan, China
Yichang Central People's Hospital (Xiling Campus)
Yichang, Hubei, China
The First People's Hospital of Changde
Changde, Hunan, China
Jilin Province FAW General Hospital
Changchun, Jilin, China
The Fifth People's Hospital of Shenyang
Shenyang, Liaoning, China
Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Zibo Central Hospital
Zibo, Shandong, China
Zibo Municipal Hospital
Zibo, Shandong, China
Jincheng General Hospital
Jincheng, Shanxi, China
The 2nd People's Hospital of Chengdu
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.